All In Biotech

Drug Trial Radar · NCT07297797

Phase II Clinical Study of HRS-9563 in Patients With Mild to Moderate Hypertension

A Multicenter, Randomized, Double-Blind, Placebo-Controlled Phase II Clinical Study to Evaluate the Efficacy and Safety of HRS-9563 in Patients With Mild to Moderate Hypertension

Last checked: Nov 20, 2026Latest source record: Jul 31, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Active, not recruitingPivotal-lookingRandomized with 238 participants. This is a heuristic, not a regulatory label.

Status

Active, not recruiting

Enrollment

238

Actual

Start

Jan 14, 2026

Primary completion

Dec 2026

Study completion Oct 2027

Sponsor

Sponsor type
Industry
First posted
Dec 22, 2025

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years, up to 75 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This study aims to evaluate the efficacy and safety of HRS-9563 in patients with mild to moderate hypertension, and to explore its appropriate dosage.

Conditions

  • Mild to Moderate Hypertension

Interventions

  • HRS-9563 InjectionDrug

    HRS-9563 Injection

  • sodium chloride injectionDrug

    sodium chloride injection

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Change from baseline in 24-hour mean systolic blood pressure assessed by ABPM at month 6Time frame: at 6 months after initiation of administration

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Beijing Anzhen Hospital, Capital Medical University

    Beijing, Beijing Municipality, China

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.